ASCO 2026: Research from Ireland
Cancer Trials Ireland is proud to highlight the clinical research and academic contributions originating from Ireland at the 2026 ASCO Annual Meeting.
This list will continue to be updated as we become aware of additional presentations, sessions and contributions involving researchers and participating sites in Ireland. If you or your colleagues are presenting and are not featured on this page, please get in touch at comms@cancertrials.ie to be added.
Saturday, May 30th
Greening a chemotherapy day ward
- Presenter: Alannah Kelly
- Time: 9:00 AM – 12:00 PM CDT
- Location: Hall A (Poster 485)
- Session: Care Delivery/Models of Care
Association of genomic and clinical factors with outcomes in advanced biliary tract cancer
- Presenter: Orla Maeve Fitzpatrick
- Time: 9:00 AM – 12:00 PM CDT
- Location: Hall A (Poster 118)
- Session: Gastrointestinal Cancer
Tracking genomic evolution in ERBB2-altered biliary tract cancer
- Presenter: Orla Maeve Fitzpatrick, MBBCh, MRCP
- Time: 9:00 AM – 12:00 PM CDT
- Location: Hall A (Poster 120)
- Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
AACR GENIE analysis to evaluate hormone receptor alterations across solid tumors
- Presenter: Niamh Coleman
- Time: 1:30 PM – 4:30 PM CDT
- Location: Hall A (Poster 270)
- Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Irish Cancer Society in the ASCO-Sponsored Patient Advocacy Booth
- Organisation: Irish Cancer Society
- Location: Exhibit Hall, Booth 13000
- Details: The Irish Cancer Society will be exhibiting at the ASCO-Sponsored Patient Advocacy Booth, located near the main entrance of the Exhibit Hall, where patient advocacy organisations from around the world share programmes, services and resources with the oncology community.
Sunday, May 31st
Irish Cancer Society in the ASCO-Sponsored Patient Advocacy Booth
- Organisation: Irish Cancer Society
- Location: Exhibit Hall, Booth 13000
- Details: The Irish Cancer Society will be exhibiting at the ASCO-Sponsored Patient Advocacy Booth, located near the main entrance of the Exhibit Hall, where patient advocacy organisations from around the world share programmes, services and resources with the oncology community.
Monday, June 1st
Co-creating patient partnership within a national cancer trials network: Experience from Cancer Trials Ireland in partnership with the Irish Cancer Society
- Presenter: Emer Mulvaney
- Time: 9:00 AM – 12:00 PM CDT
- Location: Hall A – Posters and Exhibits (Poster 44)
- Session: Quality Care/Health Services Research
Inspiring the next generation of medical oncologists: Passion, purpose, and preventing burnout.
- Presenter: Ruth Hutch, MD, MSc
- Time: 9:00 AM – 12:00 PM CDT
- Location: Hall A (Poster 482)
- Session: Medical Education and Professional Development
Risk prediction models for familial breast cancer: A Cochrane systematic review and meta-analysis
- Presenter: Sarah A. McGarrigle
- Time: 1:30 PM – 4:30 PM CDT
- Location: Hall A (Poster 506)
- Session: Prevention, Risk Reduction, and Genetics
Irish Cancer Society in the ASCO-Sponsored Patient Advocacy Booth
- Organisation: Irish Cancer Society
- Location: Exhibit Hall, Booth 13000
- Details: The Irish Cancer Society will be exhibiting at the ASCO-Sponsored Patient Advocacy Booth, located near the main entrance of the Exhibit Hall, where patient advocacy organisations from around the world share programmes, services and resources with the oncology community.
Global Research with Participation from Ireland
Ireland’s clinical trial infrastructure plays a vital role in international oncology research. The following sessions present results from global clinical trials and registries where hospital sites and patients from Ireland have made significant contributions.
| Title (Trial) | Date | Time | Location |
| Prognostic and predictive impact of baseline gene expression in the NATALEE trial (NATALEE Trial) | May 30th | 1:27 PM – 1:39 PM CDT | Hall B1 |
| Alirocumab plus cemiplimab in immuno-refractory metastatic NSCLC | May 30th | 1:30 PM – 4:30 PM CDT | Hall A – Posters and Exhibits |
| Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer | May 30th | 1:30 PM – 4:30 PM CDT | Hall A – Posters and Exhibits |
| The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (ChonDRAgon Study) | May 30th | 4:12 PM – 4:24 PM CDT | S100bc |
| Classification tree phenotypes for early treatment-limiting toxicity after androgen receptor pathway inhibitor initiation (IRONMAN Registry) | May 31st | 9:00 AM – 12:00 PM CDT | Hall A – Posters and Exhibits |
| EORTC GUCG 2238: “Deescalate,” a pragmatic trial to revisit intermittent androgen deprivation therapy (EORTC 2238) | May 31st | 9:00 AM – 12:00 PM CDT | Hall A – Posters and Exhibits |
| First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC (LOXO-RAS-20001 and SUNRAY-01) | May 31st | 9:00 AM – 12:00 PM CDT | Hall A – Posters and Exhibits |
| Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma (BelaDRd Study) | May 31st | 10:15 AM – 10:21 AM CDT | E450a |
| Transcriptomic analyses of molecular subsets and correlations with clinical outcomes (IMforte Study) | May 31st | 5:12 PM – 5:18 PM CDT | Arie Crown Theater |
| Safety and pharmacokinetics (PK) of lurbinectedin in pediatric patients with relapsed/refractory solid tumors | May 31st | 5:30 PM – 5:36 PM CDT | S504 |
| Comprehensive genomic landscape of osteosarcoma: Analysis of 1,058 patients (FOSTER Consortium) | Jun 1st | 1:30 PM – 4:30 PM CDT | Hall A – Posters and Exhibits |
| A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PIKALO-1) | Jun 1st | 1:30 PM – 4:30 PM CDT | Hall A – Posters and Exhibits |
| Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma | Jun 1st | 1:30 PM – 4:30 PM CDT | Hall A – Posters and Exhibits |
148P – Advancing federated sharing of cancer clinical and genomic data across Europe: The 1+Million Genomes Cancer Working Group Minimal Set for Cancer. Abhishek Nayak (Limerick, Ireland)(Monday)
| 2474P – Identification of a novel cluster of patients with prostate cancer in Japan with improved quality of life – results of the largest international digital survey of people affected by prostate cancer. Joe O’Sullivan (Belfast, United Kingdom) | (Saturday) |
| 2025TiP – ARTEMIDE-Lung04: A phase III, randomised, double-blind, global study of rilvegostomig or pembrolizumab monotherapy as first-line (1L) treatment for patients with metastatic non-small cell lung cancer (mNSCLC) and programmed cell death ligand-1 (PD-L1) expression ≥50%. Jarushka Naidoo (Dublin, Ireland) | (Saturday) |
| 1166P – Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. Dearbhaile C. Collins (Cork, Ireland) | (Saturday) |
| 2483P – PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304). Raymond McDermott (Dublin, Ireland) | (Saturday) |
| 2519TiP – EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors. Raymond McDermott (Dublin, Ireland) | (Saturday) |
| 3149P – A Pan-European survey of irAEs: Clinical practice and models-of-care in 32 countries. Maggie L. O’Connor (Dublin, Ireland) | (Saturday) |
| 2308P – The triple planetary crisis: Implications for Ireland’s next national cancer strategy. Hailey K. Carroll (Dublin, Ireland) | (Sunday) |
| 2857P – Vasomotor symptom alleviation through acupuncture in patients with prostate cancer: results from the VASAPRO pilot study. Zain Ul Abedin (Cork, Ireland) | (Sunday) |
| 2363P – Modelling the cost of BRCA testing strategies in ovarian cancer: Integrated vs reflex testing. Ciara S. McNevin (Dublin, Ireland) | (Sunday) |
| 421TiP –OPTImaL: Optimisation of treatment for patients with low stage triple-negative breast cancer with high stromal tumor-infiltrating lymphocytes. Adrianne L. Rolfes (Amsterdam, Netherlands) | (Monday) |
| 2994P – Insights into rare cancers: Characterizing the genomic landscape of anaplastic thyroid cancer. Ruth Hutch (Limerick, Ireland) | (Monday) |
| 376P – Oncotype-DX recurrence score (ODX RS)-guided management and long-term clinical outcomes of Irish women with node-negative (N0), oestrogen-positive (ER+), early breast cancer (EBC). Hailey K. Carroll (Dublin, Ireland) | (Monday) |
| 2048eP – Real-world survival outcomes in advanced non-small cell lung cancer (NSCLC) with driver mutations: A study from Ireland South region. Julie Twomey (Cork, Ireland) | (ePoster) |
| 427eP – Analysis of diagnostic efficacy of tomosynthesis and mammogram in male breast cancer. Abeera Mehmood (Cork, Ireland) | (ePoster) |
| 892eP – Emerging trends of early-onset colorectal cancer observed in an Irish cohort. Alice Talbot (Dublin, Ireland) | (ePoster) |
| 107eP – Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study. Raymond McDermott (Dublin, Ireland) | (ePoster) |